ACM Biolabs shines at NTUitive’s Technology Roadshow 2023

“ACM Biolabs is just one of 70 deep-tech firms spun off from Nanyang Technological University (NTU) research since 2015, enterprises that are now collectively valued at around $820 million and armed with the potential to transform a host of sectors including healthcare, robotics and artificial intelligence.” – straitstimes.com

Newspost | 14.04.2023
We are delighted to announce the appointment of David Lawrence as Non-Executive Director effective immediately. David has over 30 years’ experience of leadership roles in life sciences, ranging from large biopharma companies such as GSK to start-ups and earlier stage companies, including Synpromics Ltd. He brings with him extensive industry experience including strategy, business development and M&A, and currently sits on the Boards of Enterobiotix Limited. He is also currently CFO of Sensorion, a gene therapy company listed on Euronext Growth in Paris and is a Director at EnteroBiotix Ltd. He has also advised several life sciences Venture Capital firms between 2006 and 2017.

We look forward to working closely with David as we progress with our partnering and accelerate the growth of ACM Biolabs.

Singapore, Basel, Sydney, July 29, 2022

ACM Biolabs, a biotechnology company with operations in Singapore, Switzerland and Australia, focusing on the development of next generation vaccines for infectious diseases, personalized immunotherapy for cancer patients using its proprietary delivery platform (non-lipid, non-viral), today announced that the first subject has been dosed in the first‑in‑human Phase 1 trial of its clinical candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine with broad protection against variants of concerns, including delta and omicron demonstrated in a variety of preclinical studies by ACM Biolabs (Clinicaltrials.gov identifier NCT05385991).

About the study: The vaccine is evaluated as a booster in a phase 1, dose escalation study comparing intramuscular versus intranasal administration of various doses of antigen and adjuvant in healthy adult volunteers who have previously received 3 doses of approved Covid vaccines.

“The start of this First-in-human trial is an important milestone for ACM Biolabs. Our next generation COVID-19 vaccine ACM-001, a nasal vaccine, can make a significant contribution to block infections and transmission. The current situation of high infection and reinfection rates despite repeated booster vaccinations reinforces the emerging consensus of the scientific community that there is a high need for an intranasal COVID vaccine,” said Dr. Madhavan Nallani, Chief Executive Officer of ACM Biolabs. “We are now very much looking forward to see our promising preclinical results translate in this important Phase 1 study within the next months.”ur next generation COVID-19 vaccine ACM-001, a nasal vaccine, can make a significant contribution to block infections and transmission. The current situation of high infection and reinfection rates despite repeated booster vaccinations reinforces the emerging consensus of the scientific community that there is a high need for an intranasal COVID vaccine,” said Dr. Madhavan Nallani, Chief Executive Officer of ACM Biolabs. “We are now very much looking forward to see our promising preclinical results translate in this important Phase 1 study within the next months.”

The spike-protein component of ACM-001 is modeled after the immune-evasive beta variant. In animal studies the clinical vaccine candidate was safe and generated a protective immune response against the beta-variant and ancestral form of SARS-2. Additionally, it also elicited broadly neutralizing antibodies against other variants, including delta and omicron. Furthermore, the plug-and-play platform would allow for quick adaption for current and future mutations of the SARS-2 virus.

ACM-001 is utilizing ACM Biolabs’ innovative delivery technology, allowing administration not only via the conventional intramuscular route but also the intranasal route. The nose is the entry point for SARS-CoV-2 and the site where the virus initiates replication. Vaccine application to the mucosal surface lining the nasal cavity is deemed highly relevant and disrupts infection and potentially transmission of COVID-19. This effect could also be applicable to other respiratory infectious diseases. ACM Biolabs has published its comprehensive investigation of the significant benefits of intranasal ACM-001 (Lam JH et al., Biorxiv 2022.02.12.480188). Animals that were immunized with ACM-001 and were infected with live virus, had significantly less viral burden in their noses than their unvaccinated counterparts. Moreover, animals that had received ACM-001 through the nose, needed significantly lesser time to clear infection.

ACM Biolabs’ researchers described the exact way of how the vaccine component is delivered inside the body. The formulation facilitates uptake of the vaccine by specialized cells of the body’s own immune system (Lam JH et al., ACS Nano 2021, 15, 10, 15754–15770). These cells are highly efficient activators of T-cells, antibody-producing B-cells as well as the immune system’s memory.

“With our preclinical data we achieved not only mucosal immunity but also the same kind of systemic immunogenicity as the currently licensed vaccines”, said Pierre Vandepapeliere, M.D., PhD, Chief Medical Officer of ACM Biolabs. “Knowing that the infection and transmission of covid virus pass through the upper respiratory tract, this study will allow confirmation in human that intranasal administration induces stronger and better immune responses at the portal of virus entry than classical intramuscular administration. Utilizing this disruptive vaccine platform, ACM Biolabs has the potential to become a real game-changer in the field of vaccines, thanks to its capacity to be administered intranasally, to carry various types of vaccine antigens like proteins or mRNA, and its thermostability.”

ACM-001 vaccine is developed based on the company’s proprietary ACM (artificial cell membrane) polymer-based technology. This next generation delivery platform offers flexibility with multiple payloads (proteins to RNA) and can be stored in a refrigerator in contrast to the current LNP-based delivery. ACM Biolabs is working on a wide range of products beyond infectious disease vaccines including personalized immunotherapy for cancer patients.

For further information please contact:

For Investors: 

Dr. Alexander Breidenbach
Chief Development Officer
ACM Biosciences
+41 61 975 85 88
office@acmbiosciences.com


For media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch


About ACM Biolabs

ACM Biolabs is developing next generation vaccines for infectious diseases, immuno-modulator therapies, and personalized cancer vaccines using its proprietary ACM (Artificial Cell Membranes) polymer-based delivery platform (non-lipid, non-viral). The company’s lead program, ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine currently in Phase 1.

Founded in Singapore in 2013, ACM Biolabs has established laboratories for research and early manufacturing activities. In 2020 ACM Biosciences, a subsidiary of ACM Biolabs, was established in Basel, Switzerland, to internationalize its development activities. In 2022 ACM Biolabs Pty Ltd was established in Australia to operationalize clinical development. ACM Biosciences leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners

For further information, please visit: www.acmbiolabs.com

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of the ACM Biolabs and ACM Biosciences management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. ACM Biolabs and ACM Biosciences disclaim any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ACM Biolabs at  BioEquity Europe, Milano, May 16 -18, 2022

We are excited to inform you that Alexander Breidenbach, Chief Development Officer/Chief Business Officer ACM Biosciences, will take the opportunity to represent ACM Biolabs at BioEquity Europe, Europe’s premier international showcase for raising biotechs, taking place in Milan, Italy, May 16-18th. Dr Breidenbach will provide an overview of the company and present ACM’s versatile platform to deliver disease prevention and therapeutics and will be available to for in-person meetings with investors who are registered to attend the conference. 

#acmbiosciences #acmbiolabs #polymersomes #vaccine

View this Press Release in German

 Singapore and Basel, Switzerland, March 4, 2022 

 ACM Biolabs, a Singaporean-Swiss biotechnology company focusing on the development of prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, today announced that its first clinical candidate vaccine, ACM-001, a 2nd generation COVID vaccine, demonstrated broad protection against variants of concerns, including delta and omicron in a variety of preclinical studies. ACM-001 can be given intramuscularly as well as intranasally. 

ACM 001 vaccine is developed based on the company’s proprietary ACM (artificial cell membrane) polymer-based technology. This next generation delivery platform offers flexibility with multiple payloads (proteins to RNA) without requiring ultra-low temperatures for mRNA compared to the current lipids-based platforms. ACM is working on a wide range of products that includes vaccine for immunological therapy for cancer. 

After completion of the preclinical safety testing, the lead program, ACM-001, an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine, is ready to be tested in humans. The plug-and-play platform allows for quick adaption of the COVID vaccine for future variants as well as combinations as multi-valent vaccines. In addition to being needle and pain-free, an intranasal vaccine is expected to achieve maximum protection already in the upper airways where respiratory viruses first enter the body. 

While the currently approved vaccines resulted in attenuation or prevention of disease, they do not provide mucosal immunity and therefore do not prevent replication of virus in the nasal cavity and hence do not stop transmission of SARS-CoV-2. ACM Biolabs has now published its comprehensive investigation of the significant benefits of intranasal ACM-001 (https://acmbiolabs.com/?p=634). While cross-neutralization against variants of concern, including delta and omicron was seen after intramuscular and intranasal delivery, the virus load in the nasal cavity was 100-fold lower already at day 2 when compared with intramuscular administration suggesting a slowing down in virus spread. The reported preclinical studies have provided critical proof of concept and enabled the design of the Phase 1 clinical trial. Following the regulatory approval, which is expected in the next few weeks, healthy adults who had already received two doses of a COVID vaccine will be included in the study. 

“Currently, most of COVID-19 vaccines in use or development are administered via an intramuscular injection, which produces a rather poor mucosal immune response,” said Professor Onur Boyman, Director of the Clinic for Immunology at the University of Zurich. “Intranasal vaccination is thus an ideal approach to fight respiratory viruses. ACM-001 has now produced very promising preclinical data showing that intranasal vaccination greatly improves mucosal immune responses, which inhibit infection at the site of virus entry.” 

“We are very pleased about the intriguing properties of our ACM platform which hold great potential for the development of urgently needed next-generation Covid-19 vaccines,” said Dr. Madhavan Nallani, Chief Executive Officer of ACM Biolabs. “Now that we successfully completed all regulatory requirements including a comprehensive safety evaluation of our ACM platform and that the clinical trial material for ACM-001 is available we are excited to start the Phase 1 study of ACM-001 within the next weeks.” 

For further information please contact: 

For Investors:

Dr. Alexander Breidenbach
Chief Development Officer
ACM Biosciences
+41 61 975 85 88
office@acmbiosciences.com

For Media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch

About ACM Biolabs 

ACM Biolabs is developing prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment based on its proprietary ACM (Artificial Cell Membranes) polymer-based delivery platform technology. The companies lead program, ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine ready to move into Phase 1. 

Founded in Singapore in 2013, ACM Biolabs has established laboratories for research and early manufacturing activities. In 2020 ACM Biosciences, a subsidiary of ACM Biolabs, was established in Basel, Switzerland, to internationalize its development activities. ACM Biosciences leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners. 

For further information, please visit: www.acmbiolabs.com. 

Disclaimer 

This press release contains forward-looking statements which are based on current assumptions and forecasts of the ACM Biolabs and ACM Biosciences management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. ACM Biolabs and ACM Biosciences disclaim any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

J.P. Morgan 40th Annual Healthcare Conference 2022 DIGITAL

Date: 2022-01-10 start / 2022-01-13 end